Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDCA1 Peptide Vaccine in Advanced Prostate Cancer
NCT01225471Phase 2Unknown
- Sponsor
- Iwate Medical University
- Start
- Jun 2009
- Primary completion
- May 2011
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CDCA1-64 in prostate cancer (PCa), sponsored by Iwate Medical University. Primary endpoint: Feasibility (toxicities as assessed by NCI-CTCAE version 3) at 2 years. Status: unknown.
02
Drugs
CDCA1-64
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01225471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01225471.